Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational Results available

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

ClinicalTrials.gov ID: NCT03888365

Public ClinicalTrials.gov record NCT03888365. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Observational Study to Characterize Patient Global Impression Questions for Activity-induced Symptoms in Patients With Pulmonary Arterial Hypertension (PAH)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an observational, multicenter, single-day, Phase 2 study. This study will include a 14-day Screening Period and Study Day 1 clinic visit. Participants will be required to perform an activity to induce symptoms of PAH, and participants' severity of self-reported symptoms of PAH will be measured from pre-activity, immediately after the activity, and through the 30-minute recovery. Participants will be asked about their PAH symptoms using 3 PGI-S questions that address their overall PAH symptoms, shortness of breath, and physical fatigue.

Study identification

NCT ID
NCT03888365
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
United Therapeutics
Industry
Enrollment
43 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2019
Primary completion
Sep 18, 2019
Completion
Sep 18, 2019
Last update posted
Mar 15, 2021

2019

United States locations

U.S. sites
10
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
The University of Alabama at Birmingham Birmingham Alabama 35294
Cedars-Sinai Medical Center Beverly Hills California 90211
Santa Barbara Pulmonary Associates Santa Barbara California 93105
St. Francis Sleep, Allergy & Lung Institute Clearwater Florida 33765
Pulmonary & Critical Care of Atlanta Atlanta Georgia 30342
Kentuckiana Pulmonary Associates Louisville Kentucky 40202
Pulmonary Health Physicians, PC Fayetteville New York 13066
The Mount Sinai Hospital New York New York 10029
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27517
Rhode Island Hospital Providence Rhode Island 02903

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03888365, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 15, 2021 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03888365 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →